Zydus Life Q3 Results: Zydus Life net profit up 30% to ₹1,024 crore, revenue rises 17%; shares trade lower

Zydus Lifesciences on Wednesday reported a 29.6% jump in its net profit to ₹1,024 crore for the October-December quarter of the current fiscal (Q3 FY25), as compared to ₹790 crore posted in the year-ago period.

The company’s revenue from operations stood at ₹5,269 crore, up 17% as compared to ₹4,505 crore reported in Q3 FY24.

Following the Q3 earnings announcement, Zydus Lifesciences Limited shares are trading 1.88% down at ₹955.65 apiece on the NSE on February 5.

"We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations," said Zydus Lifesciences' Managing Director Sharvil Patel while commenting on the company's Q3 results.

Key highlights

• Earnings before interest, taxes, depreciation and amortisation (EBITDA) of the company stood at ₹1,388 crore for the reporting quarter, up 26% YoY as compared to ₹1,102 crore in Q3 FY24. EBITDA margin was 26.3% for Q3 FY25.

• For the first nine months of the current fiscal (9M FY25), the company posted a net profit of ₹3,355 crore as against ₹2,677 crore in the year-ago period.

• EBITDA for 9M FY25 was at ₹4,933 crore, up 31.4% YoY from ₹3,754 crore in 9M FY24. EBITDA margin for 9M FY25 was at 29.5%.

• In the Indian business, the company registered revenues of ₹1,947 crore in the December quarter, up 7% YoY. For the US formulations business, the registered revenues were at ₹2,410 crore in Q3 FY25, up 31% YoY. Moreover, in the International markets, the formulations business' revenues stood at ₹570 crore, up 16% YoY.